Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.

Literature DB >> 24863431

Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT.

Sandip Basu¹, Bhawna Sirohi, Shailesh V Shrikhande.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2014 PMID： 24863431 DOI： 10.1007/s00259-014-2805-8

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

19 in total

1. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors: Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914

2. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.

Authors: Günter Klöppel; Anne Couvelard; Aurel Perren; Paul Komminoth; Anne-Marie McNicol; Ola Nilsson; Aldo Scarpa; Jean-Yves Scoazec; Bertram Wiedenmann; Mauro Papotti; Guido Rindi; Ursula Plöckinger
Journal: Neuroendocrinology Date: 2009-08-28 Impact factor: 4.914

3. Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy?

Authors: Sandip Basu
Journal: J Nucl Med Date: 2013-09-26 Impact factor: 10.057

4. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: K Öberg; U Knigge; D Kwekkeboom; A Perren
Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976

5. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Authors: Samer Ezziddin; Feras Khalaf; Maria Vanezi; Torjan Haslerud; Karin Mayer; Abdullah Al Zreiqat; Winfried Willinek; Hans-Jürgen Biersack; Amir Sabet
Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-07 Impact factor: 9.236

6. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Authors: David S Klimstra; Irvin R Modlin; N Volkan Adsay; Runjan Chetty; Vikram Deshpande; Mithat Gönen; Robert T Jensen; Mark Kidd; Matthew H Kulke; Ricardo V Lloyd; Cesar Moran; Steven F Moss; Kjell Oberg; Dermot O'Toole; Guido Rindi; Marie E Robert; Saul Suster; Laura H Tang; Chin-Yuan Tzen; Mary Kay Washington; Betram Wiedenmann; James Yao
Journal: Am J Surg Pathol Date: 2010-03 Impact factor: 6.394

Review 7. A new dimension of FDG-PET interpretation: assessment of tumor biology.

Authors: Thomas C Kwee; Sandip Basu; Babak Saboury; Valentina Ambrosini; Drew A Torigian; Abass Alavi
Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-12 Impact factor: 9.236

8. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Authors: N C Turner; S J Strauss; D Sarker; R Gillmore; A Kirkwood; A Hackshaw; A Papadopoulou; J Bell; I Kayani; C Toumpanakis; F Grillo; A Mayer; D Hochhauser; R H Begent; M E Caplin; T Meyer
Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640

Review 9. PET imaging in neuroendocrine tumors: current status and future prospects.

Authors: S Basu; R Kumar; D Rubello; S Fanti; A Alavi
Journal: Minerva Endocrinol Date: 2008-09 Impact factor: 2.184

10. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors: G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal: Virchows Arch Date: 2006-09-12 Impact factor: 4.064

11 in total

1. Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed imaging.

Authors: Rudolf A Werner; Alexander Weich; Andreas Schirbel; Samuel Samnick; Andreas K Buck; Takahiro Higuchi; Hans-Jürgen Wester; Constantin Lapa
Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-09 Impact factor: 9.236

2. The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Authors: Sandip Basu; Vikas Ostwal
Journal: Eur J Nucl Med Mol Imaging Date: 2016-08-20 Impact factor: 9.236

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Authors: Sandip Basu; Sudipta Chakraborty; Rahul V Parghane; Rohit Ranade; Pradeep Thapa; Ramesh V Asopa; Geeta Sonawane; Swapna Nabar; Hemant Shimpi; Ashok Chandak; K V Vimalnath; Vikas Ostwal; Anant Ramaswamy; Manish Bhandare; Vikram Chaudhari; Shailesh V Shrikhande; Bhawna Sirohi; Ashutosh Dash; Sharmila Banerjee
Journal: Am J Nucl Med Mol Imaging Date: 2020-08-25

4. Emerging clinical applications of PET based molecular imaging in oncology: the promising future potential for evolving personalized cancer care.

Authors: Vandana K Dhingra; Abhishek Mahajan; Sandip Basu
Journal: Indian J Radiol Imaging Date: 2015 Oct-Dec

5. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.

Authors: Sandip Basu; Rohit Ranade; Pradeep Thapa
Journal: World J Nucl Med Date: 2016 Jan-Apr

6. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.

Authors: Bernhard Nilica; Dietmar Waitz; Vlado Stevanovic; Christian Uprimny; Dorota Kendler; Sabine Buxbaum; Boris Warwitz; Llanos Gerardo; Benjamin Henninger; Irene Virgolini; Margarida Rodrigues
Journal: Eur J Nucl Med Mol Imaging Date: 2016-02-27 Impact factor: 9.236

7. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.

Authors: Rudolf A Werner; Alexander Weich; Takahiro Higuchi; Jan S Schmid; Andreas Schirbel; Michael Lassmann; Vanessa Wild; Martina Rudelius; Theodor Kudlich; Ken Herrmann; Michael Scheurlen; Andreas K Buck; Saskia Kropf; Hans-Jürgen Wester; Constantin Lapa
Journal: Theranostics Date: 2017-04-05 Impact factor: 11.556

8. Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's Syndrome.

Authors: Chinna Naik; Sandip Basu
Journal: World J Nucl Med Date: 2017 Apr-Jun

9. ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites.

Authors: Pradeep Thapa; Rahul Parghane; Sandip Basu
Journal: World J Nucl Med Date: 2017 Jul-Sep

10. First Results and Experience with PRRT in South Africa.

Authors: Mariza Vorster; M R Modiselle; C S Corbett; I O Lawal; John R Buscombe; Mike M Sathekge
Journal: World J Nucl Med Date: 2018 Apr-Jun

Review 7. A new dimension of FDG-PET interpretation: assessment of tumor biology.

Review 9. PET imaging in neuroendocrine tumors: current status and future prospects.

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Review 3. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.